Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.
A new study breaks down several cases of Ozempic blindness, linked to semaglutide and tirzepatide. Here's what could be behind this.
In the glittering world of celebrity-endorsed weight loss transformations and viral before-and-after photos, a darker narrative is emerging from the shadows ...
What are semaglutide and tirzepatide? How do weight-loss injections work? The Trim Texan takes us through this popular weight-loss trend and share special savings. The advertiser paid a fee to ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
PsyPost on MSN1d
Ozempic blindness? Serious vision problems reported in patients taking weight loss medicationsA new study published JAMA Ophthalmology has brought attention to a series of vision problems observed in patients taking ...
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
Global Healthy Living Foundation Says Hims & Hers Health Super Bowl ad omits safety risks and side effects of its weight loss ...
Researchers found tirzepatide reduced urine albumin-to-creatinine ratio through direct and indirect means. Reductions in HbA1c and body weight induced by tirzepatide mediated 45.9% of the decline ...
Hosted on MSN23h
LLY Rises More Than 4% in a Week: How to Play the StockEli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...
Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback